产品: DFNA5/GSDME 抗体 - N-terminal
货号: AF4016
描述: Rabbit polyclonal antibody to DFNA5/GSDME - N-terminal
应用: WB
文献验证: WB
反应: Human, Mouse
蛋白号: O60443

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit IgG
应用:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse
克隆:
Polyclonal
特异性:
DFNA5/GSDME Antibody detects N-terminal fragment of DFNA5/GSDME.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

2310037D07Rik; 4932441K13Rik; Deafness, autosomal dominant 5; Deafness, autosomal dominant 5 protein; DFNA5; DFNA5 gene; DFNA5_HUMAN; Dfna5h; EG14210; Fin15; ICERE 1; ICERE-1; Inversely correlated with estrogen receptor expression 1; Non-syndromic hearing impairment protein 5; Nonsyndromic hearing impairment protein; Gasdermin-E;GSDME_HUMAN;ICERE1;

抗原和靶标

免疫原:

A synthesized peptide derived from human DFNA5(Accession O60443), corresponding to N-terminal amino acid.

基因/基因ID:

文献引用

1). PLGA confers upon conventional nonfluorescent molecules luminescent properties to trigger 1O2-induced pyroptosis and immune response in tumors. Journal of nanobiotechnology, 2025 (PubMed: 39844156) [IF=10.2]

Application: WB    Species: Mouse    Sample: CT26 cells

Fig. 6 (A-D) Intracellular ROS levels were measured by CLSM stained with DCFH-DA and analyzed by FCM. Scale bars: 100 μm. (E) ROS images and pyroptotic morphological changes were captured by CLSM. Vitamin C (Vc) and vitamin K3 (Vk3) were used as a 1O2 scavenger and 1O2 inducer, respectively; scale bar: 40 μm. The yellow arrows represent the pyroptotic bodies. (F) Intracellular ROS levels were measured by FCS after pretreatment with Vc or Vk3. (G) Cleavage of GSDME and caspase-3 from CT26 cells following 8-hour treatment of CUR@PLGA-NPs + Light at a concentration of 10 µM as detected by western blot analysis. (H) CLSM images showing GSDME-N expression after being treated with Control, CuET, Cisplatin, NPs + Light, CuET + NPs + Light, and Cisplatin + NPs + Light. (I) LDH release analysis showing influence of CuET and Cisplatin on NPs + Light-induced pyroptosis. (J) Schematic illustration of the proposed pyroptosis activation via 1O2 generation

Application: IF/ICC    Species: Mouse    Sample: CT26 cells

Fig. 6 (A-D) Intracellular ROS levels were measured by CLSM stained with DCFH-DA and analyzed by FCM. Scale bars: 100 μm. (E) ROS images and pyroptotic morphological changes were captured by CLSM. Vitamin C (Vc) and vitamin K3 (Vk3) were used as a 1O2 scavenger and 1O2 inducer, respectively; scale bar: 40 μm. The yellow arrows represent the pyroptotic bodies. (F) Intracellular ROS levels were measured by FCS after pretreatment with Vc or Vk3. (G) Cleavage of GSDME and caspase-3 from CT26 cells following 8-hour treatment of CUR@PLGA-NPs + Light at a concentration of 10 µM as detected by western blot analysis. (H) CLSM images showing GSDME-N expression after being treated with Control, CuET, Cisplatin, NPs + Light, CuET + NPs + Light, and Cisplatin + NPs + Light. (I) LDH release analysis showing influence of CuET and Cisplatin on NPs + Light-induced pyroptosis. (J) Schematic illustration of the proposed pyroptosis activation via 1O2 generation

2). Iron induces B cell pyroptosis through Tom20–Bax–caspase–gasdermin E signaling to promote inflammation post-spinal cord injury. Journal of Neuroinflammation, 2023 (PubMed: 37480037) [IF=9.3]

Application: WB    Species: Mouse    Sample: B cells

Fig. 3 Pyroptosis induced by iron accumulation may occur in splenic B cells after SCI. a Three days after SCI, serum samples were collected for quantification of the protein expression levels of MCP-1, IL-1β, IL-6, and TNF-α by ELISA. b Three days after SCI, injured spinal cord homogenates were collected for quantification of the protein expression levels of MCP-1, IL-1β, IL-6, and TNF-α by ELISA. c Three days after SCI, the spleen was stained with Prussian blue to detect the level of iron ion. d Three days after SCI, serum samples were collected to quantify the concentration of iron ions. e Three days after SCI, B cell lysates were collected to quantify the concentration of iron ions. f Detection of Tom20-Bax-caspase-GSDME pathway-related protein expression in B cells by western blot. g The knock-down efficiency of AAV on Tom20 in B cells was verified. h, l, m The expression levels of MCP-1, IL-1 β, IL-6, TNF- α, IgG and IgM in serum of different groups were detected by ELISA. i–k Three days after SCI, the spleens of mice were observed, and the spleen length and organ index of different groups were compared. n, o, q The spleen was taken for HE staining, Prussian blue staining, and immunofluorescence. CD19+ was red, dapi was blue, and merge was combined. p Detection of nerve evoked potentials in different groups of mice. r Detection of the expression of Tom20-Bax-caspsae-GSDME pathway-related proteins in different groups of B cells. All data are expressed as the mean ± SD (n ≥ 3 replicates per group). ns P > 0.05, * P 

3). Neuronal-specific TNFAIP1 ablation attenuates postoperative cognitive dysfunction via targeting SNAP25 for K48-linked ubiquitination. Cell communication and signaling : CCS, 2023 (PubMed: 38102610) [IF=8.4]

4). ETV5 transcriptionally inhibits KIF23 to repress pyroptosis in aged mice with perioperative neurocognitive disorders. Biochemical pharmacology, 2025 (PubMed: 40983152) [IF=5.3]

5). Neuroprotection of celastrol against postoperative cognitive dysfunction through dampening cGAS-STING signaling. Experimental neurology, 2024 (PubMed: 39369806) [IF=4.6]

6). KIF23 inhibition protects against perioperative neurocognitive disorders by hindering ROS/caspase-3/GSDME-mediated pyroptosis. Experimental neurology, 2025 (PubMed: 40639436) [IF=4.6]

7). Liproxstatin‑1 induces cell cycle arrest, apoptosis, and caspase‑3/GSDME‑dependent secondary pyroptosis in K562 cells. International Journal of Oncology, 2022 (PubMed: 36004469) [IF=4.5]

8). Pharmacological inhibition of cGAS ameliorates postoperative cognitive dysfunction by suppressing caspase-3/GSDME-dependent pyroptosis. Neurochemistry international, 2024 (PubMed: 38843953) [IF=4.4]

9). Pyropheophorbide-α methyl ester-mediated photodynamic therapy triggers pyroptosis in osteosarcoma cells via the ROS/caspase-3/GSDME pathway. Photodiagnosis and photodynamic therapy, 2024 (PubMed: 39615558) [IF=3.1]

Application: WB    Species: human    Sample: osteosarcoma 143b and HOS cells

Fig. 2. MPPa-PDT induced pyroptosis in human osteosarcoma 143b and HOS cells. (A) Morphological changes of the cells, the red arrow indicated pyroptosis cells. (B) The ultrastructure of cells was observed with an SEM. (C) GSDME-FL and GSDME-NT levels were analyzed using Western blotting. *: p < 0.05 vs. Control group.

10). Maresin1 alleviates neuroinflammation by inhibiting caspase-3/ GSDME-mediated pyroptosis in mice cerebral ischemia-reperfusion model. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2024 (PubMed: 38782167) [IF=2.0]

Application: WB    Species: Mouse    Sample:

Fig. 1. Expression of GSDME and GSDME-N after 6–72 h of reperfusion in mouse MCAO model. (A) The expression of GSDME mRNA in cerebral ischemic penumbra tissue was detected by RT-PCR; (B) GSDME and GSDME-N protein expression in cerebral ischemic penumbra tissue was analyzed by Western blot. Data were shown as the means ± SEM, n = 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.